Clinical trial
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic…
NCT03219333 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT03219333 |
|---|---|
| Title | A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer |
| Official title | A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy |
| Acronym | EV-201 |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Seagen Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms |
| Intervention type | Drug |
| Interventions | Enfortumab vedotin |
| Enrollment | 219 |
| Start date | Oct 8, 2017 |
| Primary completion | Oct 27, 2020 |
| Completion | Jul 28, 2023 |
| First posted | Jul 17, 2017 |
| Last update posted | Aug 27, 2024 |
| Countries | France, Germany, Italy, Japan, Netherlands, South Korea, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: